CDG Therapeutics, Inc. is a Chicago-based, clinical stage biotechnology company engaged in the development and commercialization of proprietary, cell penetrating peptides (CPPs) that cross the blood brain barrier, preferentially enter cancer cells, induce cancer cell cycle arrest and ultimately cell death.

CDG Therapeutics recently completed two Phase I clinical trials of our lead compound, p28, in a wide spectrum of metastatic, solid tumors and progressive, pediatric central nervous system (CNS) malignancies, the latter sponsored by the NCI-DCT CTEP and conducted by the Pediatric Brain Tumor Consortium (PBTC; PBTC-041). In addition to exhibiting extraordinary safety attributes, the Phase I trials demonstrated significant regression and extended survival in a variety of refractory adult solid tumors and extended survival in pediatric CNS tumors. These initial trials suggest that CDG Therapeutics proprietary peptides may be effective in treating a broad spectrum of advanced solid tumors while reducing the significant adverse side effects associated with most existing cancer therapies.